April 23, 2015
Ono Pharmaceutical filed its anti-PD-1 antibody Opdivo (nivolumab) for Japanese regulatory approval on April 22 for the treatment of unresectable, advanced or recurrent non-small cell lung cancer (NSCLC) except non-squamous cell carcinoma, the company said the same day. NSCLC accounts...read more